EBI3 and myeloid sarcoma: The notion that EBI3 immunoreactivity was prominent in more active lesion areas together with the observation that IL-27 expression was noted at high levels in the CSF at early stages of the disease prompted us to investigate EBI3 expression in histopathological early active lesion stages in MS biopsies [16, 17].